• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [24117 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Agency for Care Effectiveness (ACE) Antibacterial envelope for the prevention of cardiac implantable electronic device-related infections
2021     Agency for Care Effectiveness (ACE) Repetitive transcranial magnetic stimulation for adults with treatment resistant major depressive disorder
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with conductive or mixed hearing loss
2024     Agency for Care Effectiveness (ACE) Tolvaptan for treating autosomal dominant polycystic kidney disease
2022     Agency for Care Effectiveness (ACE) Active middle ear implants for patients with hearing loss
2024     Agency for Care Effectiveness (ACE) Ruxolitinib for treating graft-versus-host disease
2022     Agency for Care Effectiveness (ACE) Bone conduction hearing implants for patients with single sided deafness
2024     Agency for Care Effectiveness (ACE) Nusinersen and risdiplam for treating spinal muscular atrophy
2022     Agency for Care Effectiveness (ACE) Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2024     Agency for Care Effectiveness (ACE) Enzyme replacement therapies for Fabry disease
2021     Agency for Care Effectiveness (ACE) Golimumab for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and ulcerative colitis
2024     Agency for Care Effectiveness (ACE) Calcitonin gene-related peptide monoclonal antibodies for prophylaxis of migraine
2017     Agency for Care Effectiveness (ACE) Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
2024     Agency for Care Effectiveness (ACE) Burosumab for treating X-linked hypophosphataemia
2022     Agency for Care Effectiveness (ACE) Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory B-cell acute lymphoblastic leukaemia
2017     Agency for Care Effectiveness (ACE) Gliclazide for the treatment of type 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Trastuzumab deruxtecan for HER2-low unresectable and or metastatic breast cancer after at least one prior line of chemotherapy
2017     Agency for Care Effectiveness (ACE) Ustekinumab for the treatment of chronic plaque psoriasis and psoriatic arthritis
2024     Agency for Care Effectiveness (ACE) Selexipag for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Sodium-glucose co-transporter 2 (SGLT2) inhibitors for type 2 diabetes mellitus
2024     Agency for Care Effectiveness (ACE) Cabotegravir with rilpivirine for treating human immunodeficiency virus type 1 (HIV-1) infection
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2024     Agency for Care Effectiveness (ACE) Nirmatrelvir and ritonavir combination for treating mild-to-moderate COVID-19
2017     Agency for Care Effectiveness (ACE) Somatropin for the treatment of growth failure in children
2024     Agency for Care Effectiveness (ACE) Recombinant zoster vaccine for the prevention of herpes zoster and post-herpetic neuralgia
2017     Agency for Care Effectiveness (ACE) Gemcitabine for the treatment of cancer
2025     Agency for Care Effectiveness (ACE) Pneumococcal conjugate vaccines (15-valent and 20-valent) for the prevention of pneumococcal disease in adults
2017     Agency for Care Effectiveness (ACE) Sumatriptan for the treatment of acute migraine attacks
2025     Agency for Care Effectiveness (ACE) Triple therapy inhalers for treating asthma or chronic obstructive pulmonary disease
2017     Agency for Care Effectiveness (ACE) Temozolomide for the treatment of malignant glioma
2024     Agency for Care Effectiveness (ACE) Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2017     Agency for Care Effectiveness (ACE) Insulin glargine biosimilar (Basaglar) for the treatment of type 1 and type 2 diabetes mellitus
2022     Agency for Care Effectiveness (ACE) Guardant360 CDx for patients with locally advanced or metastatic non-small cell lung cancer
2025     Agency for Care Effectiveness (ACE) Sacituzumab govitecan for unresectable locally advanced or metastatic HR-positive, HER2-negative breast cancer
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for the management of focal spasticity of the upper limbs associated with stroke in adults
2022     Agency for Care Effectiveness (ACE) The Signatera test for patients previously diagnosed with cancer
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer
2019     Agency for Care Effectiveness (ACE) Ticagrelor for preventing thrombotic events in adults with acute coronary syndromes
2025     Agency for Care Effectiveness (ACE) Pembrolizumab for treating locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma
2018     Agency for Care Effectiveness (ACE) Ivabradine for the treatment of chronic stable angina and chronic heart failure
2025     Agency for Care Effectiveness (ACE) Glofitamab for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy
2018     Agency for Care Effectiveness (ACE) Rivastigmine for the treatment of dementia associated with Alzheimer's disease or Parkinson's disease
2022     Agency for Care Effectiveness (ACE) Sitagliptin for treating type 2 diabetes mellitus
2025     Agency for Care Effectiveness (ACE) Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
2022     Agency for Care Effectiveness (ACE) Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the treatment and secondary prevention of venous thromboembolism
2022     Agency for Care Effectiveness (ACE) Tofacitinib, ustekinumab and vedolizumab for treating inflammatory bowel disease
2024     Agency for Care Effectiveness (ACE) Dostarlimab for treating dMMR or MSI-H primary advanced or recurrent endometrial cancer
2018     Agency for Care Effectiveness (ACE) LAMA & LAMA/LABA for chronic obstructive pulmonary disease (COPD)
2022     Agency for Care Effectiveness (ACE) Emicizumab prophylaxis for patients with haemophilia A
2025     Agency for Care Effectiveness (ACE) Deucravacitinib for moderate-to-severe chronic plaque psoriasis
2020     Agency for Care Effectiveness (ACE) Dutasteride, tamsulosin, alfuzosin and dutasteride/tamsulosin combination for treating benign prostatic hyperplasia
2022     Agency for Care Effectiveness (ACE) Nivolumab for treating gastroesophageal cancers
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for second-line relapsed or refractory large B-cell lymphoma
2018     Agency for Care Effectiveness (ACE) Solifenacin for treating overactive bladder
2022     Agency for Care Effectiveness (ACE) Gemtuzumab ozogamicin for untreated de novo CD33-positive acute myeloid leukaemia
2024     Agency for Care Effectiveness (ACE) Axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 1 chronic hepatitis C
2022     Agency for Care Effectiveness (ACE) SGLT2 inhibitors for treating heart failure with reduced ejection fraction and chronic kidney disease
2018     Agency for Care Effectiveness (ACE) Second-generation antipsychotic injections for treating schizophrenia
2022     Agency for Care Effectiveness (ACE) Cabozantinib in combination with nivolumab for previously untreated advanced renal cell cancer
2018     Agency for Care Effectiveness (ACE) Lanthanum carbonate and sevelamer carbonate for treating hyperphosphataemia in patients with chronic kidney disease
2022     Agency for Care Effectiveness (ACE) Tyrosine kinase inhibitors for treating MET mutation-positive metastatic non-small-cell lung cancer
2020     Agency for Care Effectiveness (ACE) Direct-acting antiviral agents for treating genotype 2 to 6 chronic hepatitis C
2019     Agency for Care Effectiveness (ACE) Nintedanib and pirfenidone for treating idiopathic pulmonary fibrosis
2019     Agency for Care Effectiveness (ACE) Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
2019     Agency for Care Effectiveness (ACE) Omalizumab for treating antihistamine-resistant chronic spontaneous urticaria
2019     Agency for Care Effectiveness (ACE) Vedolizumab for treating ulcerative colitis and Crohn's disease
2022     Agency for Care Effectiveness (ACE) Sacubitril/valsartan for treating chronic heart failure with reduced ejection fraction
2020     Agency for Care Effectiveness (ACE) Pulmonary surfactant for treating respiratory distress syndrome in premature infants
2019     Agency for Care Effectiveness (ACE) Febuxostat for treating chronic hyperuricaemia in adults with gout
2020     Agency for Care Effectiveness (ACE) Ursodeoxycholic acid for treating primary biliary cirrhosis
2019     Agency for Care Effectiveness (ACE) Ezetimibe and ezetimibe/simvastatin for treating primary hypercholesterolaemia
2019     Agency for Care Effectiveness (ACE) Rifaximin for reducing recurrent episodes of overt hepatic encephalopathy
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating blepharospasm or hemifacial spasm
2019     Agency for Care Effectiveness (ACE) Oral COX-2 inhibitors for treating pain
2019     Agency for Care Effectiveness (ACE) Ferric carboxymaltose for treating iron deficiency anaemia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating cervical dystonia
2019     Agency for Care Effectiveness (ACE) Botulinum toxin A for treating focal spasticity of the upper or lower limbs in children with cerebral palsy
2019     Agency for Care Effectiveness (ACE) Endothelin receptor antagonists for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Intravenous proton pump inhibitors for gastric anti-secretory treatment when oral therapies are unsuitable
2020     Agency for Care Effectiveness (ACE) Budesonide prolonged-release tablet for treating mild to moderate active ulcerative colitis
2020     Agency for Care Effectiveness (ACE) Epoprostenol for treating pulmonary arterial hypertension
2020     Agency for Care Effectiveness (ACE) Vonoprazan for treating helicobacter pylori infection
2020     Agency for Care Effectiveness (ACE) Blinatumomab for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia
2020     Agency for Care Effectiveness (ACE) Trastuzumab for treating HER2-positive breast and gastric cancers
2020     Agency for Care Effectiveness (ACE) Antiretroviral therapies for treating human immunodeficiency virus type 1 (HIV-1) infection
2020     Agency for Care Effectiveness (ACE) Benralizumab, mepolizumab and omalizumab for treating severe asthma
2020     Agency for Care Effectiveness (ACE) Mycophenolate mofetil for immunosuppression
2020     Agency for Care Effectiveness (ACE) Adalimumab for treating inflammatory conditions
2020     Agency for Care Effectiveness (ACE) Abiraterone for treating metastatic prostate cancer
2021     Agency for Care Effectiveness (ACE) Rituximab for treating non-Hodgkin's lymphoma and chronic lymphocytic leukaemia
2022     Agency for Care Effectiveness (ACE) Infliximab biosimilar for treating inflammatory conditions
2022     Agency for Care Effectiveness (ACE) Biologics and Janus kinase inhibitors after conventional disease modifying antirheumatic drugs for treating rheumatoid arthritis
2021     Agency for Care Effectiveness (ACE) Tenofovir alafenamide for treating chronic hepatitis B infection
2021     Agency for Care Effectiveness (ACE) Metformin extended release for treating type 2 diabetes mellitus
2021     Agency for Care Effectiveness (ACE) Guselkumab, ixekizumab and secukinumab for treating chronic plaque psoriasis
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active psoriatic arthritis
2021     Agency for Care Effectiveness (ACE) Dacomitinib for treating EGFR mutation-positive non-small-cell lung cancer
2021     Agency for Care Effectiveness (ACE) Ixekizumab and secukinumab for treating active ankylosing spondylitis